{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T20:50:56Z","timestamp":1785617456239,"version":"3.56.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Indian J Pediatr"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s12098-025-05886-z","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T06:09:55Z","timestamp":1764828595000},"page":"100-104","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Continuum of Care for Hemophilia: The Story of India"],"prefix":"10.1007","volume":"93","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6624-082X","authenticated-orcid":false,"given":"Shubha R.","family":"Phadke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,4]]},"reference":[{"key":"5886_CR1","first-page":"361","volume":"9","author":"JB Chatterjea","year":"1961","unstructured":"Chatterjea JB, Kundu HB. Characteristic study of hemophilia syndrome. J Assoc Physicians India. 1961;9:361\u20137.","journal-title":"J Assoc Physicians India"},{"key":"5886_CR2","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1007\/s12288-018-1059-1","volume":"35","author":"K Ghosh","year":"2019","unstructured":"Ghosh K. Evolution of hemophilia care in India. Indian J Hematol Blood Transfus. 2019;35:716\u201321.","journal-title":"Indian J Hematol Blood Transfus"},{"key":"5886_CR3","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1111\/j.1365-2516.2007.01483.x","volume":"13","author":"A Kar","year":"2007","unstructured":"Kar A, Mirkazemi R, Singh P, et al. Disability in Indian patients with haemophilia. Haemophilia. 2007;13:398\u2013404.","journal-title":"Haemophilia"},{"key":"5886_CR4","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s12288-011-0084-0","volume":"27","author":"S Phadke","year":"2011","unstructured":"Phadke S. Hemophilia care in India: a review and experience from a tertiary care centre in Uttar Pradesh. Indian J Hematol Blood Transfus. 2011;27:121\u20136.","journal-title":"Indian J Hematol Blood Transfus"},{"key":"5886_CR5","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.vhri.2016.11.003","volume":"12","author":"P Singh","year":"2017","unstructured":"Singh P, Mukherjee K. Cost-benefit analysis and assessment of quality of care in patients with hemophilia undergoing treatment at National Rural Health Mission in Maharashtra, India. Value Health Reg Issues. 2017;12:101\u20136.","journal-title":"Value Health Reg Issues"},{"key":"5886_CR6","first-page":"63","volume":"91","author":"M De","year":"1990","unstructured":"De M, Banerjee D, Chandra S, Bhattacharya DK. HBV & HIV seropositivity in multi-transfused haemophilics & thalassaemics in Eastern India. Indian J Med Res. 1990;91:63\u20136.","journal-title":"Indian J Med Res"},{"key":"5886_CR7","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/j.1365-2516.1996.tb00157.x","volume":"2","author":"VP Choudhry","year":"1996","unstructured":"Choudhry VP, Kashyap R, Saxena R. Management of haemophilia in developing countries: an Indian experience. Haemophilia. 1996;2:141\u20134.","journal-title":"Haemophilia"},{"key":"5886_CR8","doi-asserted-by":"publisher","first-page":"472","DOI":"10.4103\/ijmr.ijmr_1941_21","volume":"155","author":"H Sait","year":"2022","unstructured":"Sait H, Sajjan SM, Phadke SR. Haemophilia management programme: transformation during COVID-19. Indian J Med Res. 2022;155:472\u20137.","journal-title":"Indian J Med Res"},{"key":"5886_CR9","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1056\/NEJMoa067659","volume":"357","author":"MJ Manco-Johnson","year":"2007","unstructured":"Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007;357:535\u201344.","journal-title":"N Engl J Med"},{"key":"5886_CR10","doi-asserted-by":"crossref","unstructured":"Srivastava A, Santagostino E, Dougall A, et al. WFH Guidelines for the Management of Hemophilia Panelists and Co-authors. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia. 2020;26:S1\u201358. Erratum in: Haemophilia. 2021;27:699.","DOI":"10.1111\/hae.14046"},{"key":"5886_CR11","doi-asserted-by":"crossref","unstructured":"Sachdeva A, Gunasekaran V, Ramya HN, et al; \u2018Consensus in Diagnosis and Management of Hemophilia\u2019 Committee*, Indian Academy of Pediatrics. Consensus statement of the Indian Academy of Pediatrics in diagnosis and management of hemophilia. Indian Pediatr. 2018;55:582\u201390.","DOI":"10.1007\/s13312-018-1302-8"},{"key":"5886_CR12","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1016\/j.jtha.2024.05.026","volume":"22","author":"SM Rezende","year":"2024","unstructured":"Rezende SM, Neumann I, Angchaisuksiri P, et al. International Society on Thrombosis and Haemostasis clinical practice guideline for treatment of congenital hemophilia A and B based on the grading of recommendations assessment, development, and evaluation methodology. J Thromb Haemost. 2024;22:2629\u201352.","journal-title":"J Thromb Haemost"},{"key":"5886_CR13","first-page":"e58941","volume":"16","author":"N Gupta","year":"2024","unstructured":"Gupta N, Dutta A, Ahmed B, et al. Expert opinions on the management of hemophilia A in India: the role of Emicizumab. Cureus. 2024;16:e58941.","journal-title":"Cureus"},{"key":"5886_CR14","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1007\/s00277-003-0704-3","volume":"82","author":"R Ahmed","year":"2003","unstructured":"Ahmed R, Kannan M, Choudhry VP, Saxena R. Mutation reports: Intron 1 and 22 inversions in Indian haemophilics. Ann Hematol. 2003;82:546\u20137.","journal-title":"Ann Hematol"},{"key":"5886_CR15","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1111\/ijlh.13715","volume":"44","author":"N Agrawal","year":"2022","unstructured":"Agrawal N, Kumar R, Masih S, et al. Molecular analysis of severe hemophilia B in Indian families: identification of mutational hotspot and novel variants. Int J Lab Hematol. 2022;44:186\u201392.","journal-title":"Int J Lab Hematol"},{"key":"5886_CR16","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.cca.2007.11.030","volume":"389","author":"R Ranjan","year":"2008","unstructured":"Ranjan R, Biswas A, Meena A, et al. Importance of investigating somatic and germline mutations in hemophilia A: a preliminary study from All India Institute of Medical Sciences, India. Clin Chim Acta. 2008;389:103\u20138.","journal-title":"Clin Chim Acta"},{"key":"5886_CR17","first-page":"120","volume":"6","author":"GS Pandey","year":"2003","unstructured":"Pandey GS, Panigrahi I, Phadke SR, Mittal B. Knowledge and attitudes towards haemophilia: the family side and role of haemophilia societies. Community Genet. 2003;6:120\u20132.","journal-title":"Community Genet"},{"key":"5886_CR18","doi-asserted-by":"crossref","unstructured":"Matsushita T, Shapiro A, Abraham A, et al; Explorer7 Investigators. Phase 3 trial of concizumab in hemophilia with inhibitors. N Engl J Med. 2023;389:783\u201394.","DOI":"10.1056\/NEJMoa2216455"},{"key":"5886_CR19","doi-asserted-by":"publisher","first-page":"e891","DOI":"10.1016\/S2352-3026(24)00307-7","volume":"11","author":"P Chowdary","year":"2024","unstructured":"Chowdary P, Angchaisuksiri P, Apte S, et al. Concizumab prophylaxis in people with haemophilia A or haemophilia B without inhibitors (explorer8): a prospective, multicentre, open-label, randomised, phase 3a trial. Lancet Haematol. 2024;11:e891\u2013904.","journal-title":"Lancet Haematol"},{"key":"5886_CR20","doi-asserted-by":"publisher","first-page":"2966","DOI":"10.1182\/blood.2024027008","volume":"145","author":"G Young","year":"2025","unstructured":"Young G, Kavakli K, Klamroth R, et al. Safety and efficacy of a fitusiran antithrombin-based dose regimen in people with hemophilia A or B: the ATLAS-OLE study. Blood. 2025;145:2966\u201377.","journal-title":"Blood"},{"key":"5886_CR21","doi-asserted-by":"crossref","unstructured":"Ozelo MC, Mahlangu J, Pasi KJ, et al; GENEr8-1 Trial Group. Valoctocogene roxaparvovec gene therapy for hemophilia A. N Engl J Med. 2022;386:1013\u201325.","DOI":"10.1056\/NEJMoa2113708"},{"key":"5886_CR22","doi-asserted-by":"crossref","unstructured":"Mahlangu J, Kaczmarek R, von Drygalski A, et al; GENEr8-1 Trial Group. Two-year outcomes of valoctocogene roxaparvovec therapy for hemophilia A. N Engl J Med. 2023;388:694\u2013705.","DOI":"10.1056\/NEJMoa2211075"},{"key":"5886_CR23","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1055\/s-0044-1787190","volume":"51","author":"G Castaman","year":"2025","unstructured":"Castaman G, Miesbach W. Gene therapy for hemophilia B: achievements, open issues, and perspectives. Semin Thromb Hemost. 2025;51:41\u20138.","journal-title":"Semin Thromb Hemost"},{"key":"5886_CR24","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1056\/NEJMoa2410597","volume":"392","author":"A Srivastava","year":"2025","unstructured":"Srivastava A, Abraham A, Aboobacker F, et al. Lentiviral gene therapy with CD34\u2009+\u2009hematopoietic cells for hemophilia A. N Engl J Med. 2025;392:450\u20137.","journal-title":"N Engl J Med"},{"key":"5886_CR25","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/hae.15125","volume":"31","author":"P Chowdary","year":"2025","unstructured":"Chowdary P, Duran B, Batty P, et al. UKHCDO gene therapy taskforce: guidance for implementation of haemophilia gene therapy into routine clinical practice for adults. Haemophilia. 2025;31:26\u201338.","journal-title":"Haemophilia"}],"container-title":["Indian Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12098-025-05886-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12098-025-05886-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12098-025-05886-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T20:01:39Z","timestamp":1785614499000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12098-025-05886-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,4]]},"references-count":25,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["5886"],"URL":"https:\/\/doi.org\/10.1007\/s12098-025-05886-z","relation":{},"ISSN":["0019-5456","0973-7693"],"issn-type":[{"value":"0019-5456","type":"print"},{"value":"0973-7693","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,4]]},"assertion":[{"value":"18 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"None.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}